Therapeutic Human Monoclonal Antibodies from COVID-19 Recovered Patient Sera

At present, some research institutions are using this technical solution. This method requires abundant clinical resources to obtain a sufficient number of B cells to select high-quality candidate antibodies. While, as the cells are isolated directly from the patient, 1-2 months of animal immunization time can be waived, so the early development will be faster, and existing research institutions have completed the screening of candidate antibodies and the construction of antibody-expressing cell lines.